MedTrace Logo

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

NCT02974179 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2020-03-12

No results posted yet for this study

Summary

Subjects from the AG-CLI-0206 phase 3 study that received AMG0001 will be eligible for the AG-CLI-0206-LTFU study

Conditions

  • Critical Limb Ischemia

Interventions

BIOLOGICAL

Subjects from Study AG-CLI-0206 who received AMG0001

Subjects from Study AG-CLI-0206 who received the study product AMG0001

Sponsors & Collaborators

  • AnGes USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Powell, MD · Dartmouth-Hitchcock Medical Center

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2020-01-10
Completion
2020-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974179 on ClinicalTrials.gov